Biocon Biologics Limited (BBL), Research and Development (RND), Biocon Park, Bommasandra Jigani Link Road, Bangalore, 560 099, India.
Biocon Biologics Limited (BBL), Research and Development (RND), Biocon Park, Bommasandra Jigani Link Road, Bangalore, 560 099, India.
Protein Expr Purif. 2021 Sep;185:105895. doi: 10.1016/j.pep.2021.105895. Epub 2021 May 3.
Biopharmaceutical development demands appropriate understanding of product related variants, which are formed due to post-translational modification and during downstream processing. These variants can lead to low yield, reduced biological activity, and suboptimal product quality. In addition, these variants may undergo immune reactions, henceforth need to be appropriately controlled to ensure consistent product quality and patient safety. Deamidation of insulin is the most common post-translational modification occurring in insulin and insulin analogues. Asn desamido variant is also the most prominent product variant formed during human insulin manufacturing process and/or during the storage. Often, this deamidated variant is used as an impurity standard during in-process and final product analysis in the QC system. However, purification of large quantity of purified deamidated material is always being challenging due to highly similar mass, ionic, hydrophobic properties, and high structural similarity of the variant compared to the parent product. Present work demonstrates the simplified and efficient scalable process for generation of Asn deamidated variant in powder form with ~96% purity. The mixed-mode property of anion exchange resin PolyQuat was utilized to purify the deamidated impurity with high recovery. Subsequent reversed-phase high performance liquid chromatography (RP-HPLC) step was introduced for concentration of product in bind elute mode. Elution pool undergone isoelectric precipitation and lyophilisation. The lyophilized product allows users for convenient use of the deamidated impurity for intended purposes. Detailed characterization by Mass spectrometry revealed deamidation is at Asn and further confirmed that, structural and functional characterization as well as the biological activity of isolated variant is equivalent to insulin.
生物制药的发展需要对产品相关变体有适当的了解,这些变体是由于翻译后修饰和下游加工过程中形成的。这些变体可能导致产量降低、生物活性降低和产品质量不佳。此外,这些变体可能会引起免疫反应,因此需要进行适当的控制,以确保产品质量和患者安全的一致性。胰岛素的脱酰胺是胰岛素和胰岛素类似物中最常见的翻译后修饰。Asn 去酰胺变体也是人胰岛素制造过程中和/或储存过程中形成的最突出的产品变体。通常,这种脱酰胺变体在 QC 系统的过程中和最终产品分析中用作杂质标准。然而,由于与母体产品相比,变体的质量、离子、疏水性和结构相似性非常相似,因此大量纯化脱酰胺物质总是具有挑战性。本工作展示了一种简化且高效的可扩展工艺,用于以 ~96%的纯度生成粉末状的 Asn 脱酰胺变体。阴离子交换树脂 PolyQuat 的混合模式特性用于高回收纯化脱酰胺杂质。随后引入反相高效液相色谱 (RP-HPLC) 步骤,以结合洗脱模式浓缩产物。洗脱液进行等电沉淀和冷冻干燥。冻干产品允许用户方便地将脱酰胺杂质用于预期目的。质谱详细表征揭示脱酰胺是在 Asn 上,进一步证实,分离变体的结构和功能表征以及生物活性与胰岛素相当。